{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:16:11Z","timestamp":1768479371217,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":5046,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1177\/1087057108318757","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T21:36:15Z","timestamp":1212010575000},"page":"456-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["High-Content Assay to Study Protein Prenylation"],"prefix":"10.1016","volume":"13","author":[{"given":"Marjo","family":"Simonen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Ibig-Rehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Magnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Heidinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1177\/1087057108318757_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-291X(03)00323-1","article-title":"Protein prenylation: a pivotal posttranslational process.","volume":"303","author":"Roskoski","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1177\/1087057108318757_bib2","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1073\/pnas.79.11.3637","article-title":"Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses.","volume":"79","author":"Der","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1177\/1087057108318757_bib3","first-page":"292","article-title":"Inhibition of ras oncogene: a novel approach to antineoplastic therapy.","volume":"7","author":"Scharovsky","year":"2000","journal-title":"J Biomed Sci"},{"key":"10.1177\/1087057108318757_bib4","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/PL00000802","article-title":"Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.","volume":"58","author":"Tamanoi","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.1177\/1087057108318757_bib5","first-page":"153","article-title":"Tomorrow\u2019s anticancer agents: inhibitors of Ras farnesylation.","volume":"89","author":"Perrin","year":"2000","journal-title":"EXS"},{"key":"10.1177\/1087057108318757_bib6","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0006-2952(00)00386-5","article-title":"Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics.","volume":"60","author":"Cohen","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1177\/1087057108318757_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/156800906775471743","article-title":"Anti-cancer therapy: targeting the mevalonate pathway.","volume":"6","author":"Swanson","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1177\/1087057108318757_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/abbi.1999.1502","article-title":"Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.","volume":"373","author":"Bergstrom","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1177\/1087057108318757_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1177\/1087057108318757_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1006\/bbrc.1999.1849","article-title":"Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway.","volume":"266","author":"Keller","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1177\/1087057108318757_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.","volume":"264","author":"van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"suppl 4","key":"10.1177\/1087057108318757_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.","volume":"9","author":"Conte","year":"2004","journal-title":"Oncologist"},{"key":"10.1177\/1087057108318757_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S8756-3282(98)00120-3","article-title":"Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships.","volume":"23","author":"van Beek","year":"1998","journal-title":"Bone"},{"key":"10.1177\/1087057108318757_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrd2221","article-title":"Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.","volume":"6","author":"Konstantinopoulos","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1177\/1087057108318757_bib15","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","article-title":"Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.","volume":"69","author":"Thompson","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1177\/1087057108318757_bib16","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1359\/jbmr.1998.13.11.1668","article-title":"Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1177\/1087057108318757_bib17","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1124\/mol.105.011163","article-title":"Chemical-based translational induction of luciferase expression: an efficient tool for in vivo screening of protein farnesylation inhibitors.","volume":"67","author":"Boijoux","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1177\/1087057108318757_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0092-8674(00)80607-8","article-title":"Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi.","volume":"98","author":"Choy","year":"1999","journal-title":"Cell"},{"key":"10.1177\/1087057108318757_bib19","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/0092-8674(89)90054-8","article-title":"All ras proteins are polyisoprenylated but only some are palmitoylated.","volume":"57","author":"Hancock","year":"1989","journal-title":"Cell"},{"key":"10.1177\/1087057108318757_bib20","first-page":"1901","article-title":"Novel determinants of H-Ras plasma membrane localization and transformation.","volume":"13","author":"Willumsen","year":"1996","journal-title":"Oncogene"},{"key":"10.1177\/1087057108318757_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0076-6879(06)14010-0","article-title":"A live cell, image-based approach to understanding the enzymology and pharmacology of 2-bromopalmitate and palmitoylation.","volume":"414","author":"Mikic","year":"2006","journal-title":"Methods Enzymol"},{"key":"10.1177\/1087057108318757_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0076-6879(05)07012-6","article-title":"Analysis of ras activation in living cells with GFP-RBD.","volume":"407","author":"Bivona","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1177\/1087057108318757_bib23","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1242\/jcs.02300","article-title":"Single-molecule diffusion measurements of H-Ras at the plasma membrane of live cells reveal microdomain localization upon activation.","volume":"118","author":"Lommerse","year":"2005","journal-title":"J Cell Sci"},{"key":"10.1177\/1087057108318757_bib24","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1126\/science.1105654","article-title":"An acylation cycle regulates localization and activity of palmitoylated Ras isoforms.","volume":"307","author":"Rocks","year":"2005","journal-title":"Science"},{"key":"10.1177\/1087057108318757_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1006\/excr.1996.0286","article-title":"Subcellular localization of the small GTPase Rab5a in resting and stimulated human neutrophils.","volume":"227","author":"Vita","year":"1996","journal-title":"Exp Cell Res"},{"key":"10.1177\/1087057108318757_bib26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1006\/jmcc.2002.2073","article-title":"TGFbeta regulates the expression of G alpha(i2) via an effect on the localization of ras.","volume":"34","author":"Ward","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1177\/1087057108318757_bib27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/protein\/12.12.1035","article-title":"Attenuation of green fluorescent protein half-life in mammalian cells.","volume":"12","author":"Corish","year":"1999","journal-title":"Protein Eng"},{"key":"10.1177\/1087057108318757_bib28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/01.cad.0000176500.56057.66","article-title":"Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.","volume":"16","author":"Knight","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1177\/1087057108318757_bib29","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines.","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1177\/1087057108318757_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/adt.2007.057","article-title":"Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay.","volume":"5","author":"Glickman","year":"2007","journal-title":"Assay Drug Dev Technol"},{"key":"10.1177\/1087057108318757_bib31","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1517\/13543776.11.9.1371","article-title":"Bisphosphonates: mechanisms of action.","volume":"11","author":"Fleisch","year":"2001","journal-title":"Expert Opin Ther Patents"},{"key":"10.1177\/1087057108318757_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0378-5173(97)00094-X","article-title":"The effect of zoledronate and pamidronate on the intestinal permeability barrier in vitro and in vivo.","volume":"153","author":"Green","year":"1997","journal-title":"Int J Pharm"},{"key":"10.1177\/1087057108318757_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0378-4347(00)00620-4","article-title":"Analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors using liquid chromatography-electrospray mass spectrometry.","volume":"754","author":"Park","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1177\/1087057108318757_bib34","first-page":"563","article-title":"Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.","volume":"2","author":"Shi","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1177\/1087057108318757_bib35","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/S0968-0896(99)00252-7","article-title":"Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors.","volume":"7","author":"Qian","year":"1999","journal-title":"Bioorg Med Chem"},{"key":"10.1177\/1087057108318757_bib36","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2174\/092986706777935078","article-title":"Inhibitors of protein: geranylgeranyl transferases.","volume":"13","author":"El Oualid","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1177\/1087057108318757_bib37","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1021\/jm9900873","article-title":"Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.","volume":"42","author":"Vasudevan","year":"1999","journal-title":"J Med Chem"},{"key":"10.1177\/1087057108318757_bib38","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.","volume":"272","author":"Whyte","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1177\/1087057108318757_bib39","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","article-title":"Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.","volume":"15","author":"Coxon","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1177\/1087057108318757_bib40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nchembio818","article-title":"Therapeutic intervention based on protein prenylation and associated modifications.","volume":"2","author":"Gelb","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1177\/1087057108318757_bib41","doi-asserted-by":"crossref","first-page":"27224","DOI":"10.1074\/jbc.272.43.27224","article-title":"The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0\/G1 and induces p21(WAF1\/CIP1\/SDI1) in a p53-independent manner.","volume":"272","author":"Vogt","year":"1997","journal-title":"J Biol Chem"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1087057108318757","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555222082211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555222082211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1087057108318757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T11:33:14Z","timestamp":1762860794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555222082211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S2472555222082211"],"URL":"https:\/\/doi.org\/10.1177\/1087057108318757","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Content Assay to Study Protein Prenylation","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1177\/1087057108318757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Society for Laboratory Automation and Screening. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}